The research results of CT071 presented by Coji Pharmaceutical-B (02171) at the 2025 EHA Annual Meeting.

The Zhixin Finance APP reported that Koji Pharmaceuticals-B (02171) announced that the results of a clinical trial (NCT06407947) initiated by researchers using CT071 (an autologous CAR-T cell product targeting GPRC5D) for the treatment of newly diagnosed multiple myeloma (NDMM) were presented at the 30th European Hematology Association (EHA) annual meeting.